FibroGen (FGEN) announced the appointment of David DeLucia to CFO, effective December 16, 2024. The company previously announced that Juan Graham would step down on December 15, 2024. Reporting to CEO, Thane Wettig, DeLucia will lead and oversee FibroGen’s global finance organization. He has most recently served as FibroGen’s Vice President, Head of Corporate Financial Planning and Analysis, Investor Relations, and Treasury.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on FGEN:
- FibroGen Reports Strong Q3 Growth and Future Plans
- FGEN Upcoming Earnings Report: What to Expect?
- Disc Medicine appoints Kaushik as Chief Technical Officer
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
